Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of atazanavir administered with and without ritonavir on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone in healthy subjects.

Trial Profile

Effect of atazanavir administered with and without ritonavir on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2011

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir; Rosiglitazone
  • Indications HIV infections; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 31 Oct 2007 Status change from in progress to completed.
    • 16 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top